Table 2.
Radiogenomic features of glioma biomarkers
| Glioma biomarker | Features | |
|---|---|---|
| 1 | IDH | IDH mutant |
| Predominantly hypoenhancing diffuse gliomas | ||
| 80% LGG and 10% GBM | ||
| Better survival | ||
| IDH wild type | ||
| Predominantly enhancing gliomas | ||
| 90% of GBM | ||
| Worse survival | ||
| 2 | 1P/19q codeletion | 30% of LGG |
| 1P/19q codeletion + IDH mutant glioma | ||
| Defines oligodendroglioma | ||
| “poorly circumscribed” margins | ||
| 1P/19q non codeletion + / − IDH mutant glioma | ||
| Defines astrocytoma | ||
| “circumscribed” margins | ||
| (T2-FLAIR mismatch) pattern | ||
| 3 | MGMT mutation | 33–57% of diffuse glioma patients |
| Better prognosis | ||
| 4 | EGFR mutation | 40% of glioblastoma patients |
| Splice variant (EGFRvIII) | ||
| 31% of glioblastoma |
IDH isocitrate dehydrogenase, MGMT methylation of O-6-methylguanine-DNA-methyltransferase, EGFR epidermal growth factor receptor